Past News
2022.11.24
SymBio enters into Material Transfer Agreement with Penn State College of Medicine for a non-clinical study to evaluate the efficacy of brincidofovir in a polyomavirus model
2022.11.08
Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.11.08
Revision to Earnings Forecast for FY 2022
2022.09.27
Chimerix announces closing of brincidofovir sale to Emergent BioSolutions
2022.08.31
Notice of Appointment of Corporate Officer
2022.08.22
SymBio submits clinical trial notification to TGA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation in Australia
2022.08.09
The National Institute of Neurological Disorders and Stroke and SymBio Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of brincidofovir (BCV) against Epstein Barr virus (EBV)
2022.08.05
Analyst Report[Update report] (Shared Research)
2022.08.04
Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.08.04
Revision to Earnings Forecast for FY 2022
2022.07.11
SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM liquid formulation
2022.06.16
Notice of Resignation of Director
2022.06.14
SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
2022.06.13
SymBio announces status of market adoption of the 10-minute Rapid Infusion (RI) administration of the TREAKISYM Liquid Formulation
2022.06.08
Analyst Report[Basic Report] (Fair Research)
2022.06.03
Analyst Report[Full report] (Shared Research)
2022.06.01
Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
2022.05.24
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2022.05.18
Chimerix announces sale of brincidofovir to Emergent BioSolutions
2022.05.16
Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
2022.05.11
Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
2022.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
2022.04.01
Joint research agreement with the National Cancer Center on rare cancers
2022.03.31
Notice of Renewal of Syndicated Loan Agreement
2022.03.30
Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
2022.03.29
Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
2022.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2022.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2022.03.25
Analyst Report[Full report] (Shared Research)
2022.03.09
Information on Shareholders' Meeting: Updated the Page
2022.03.08
SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
2022.03.07
SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
2022.02.28
SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
2022.02.25
Response to marketing approvals of generic products
2022.02.24
Notification of Amendments to the Articles of Incorporation
2022.02.24
Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
2022.02.24
SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
2022.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
2022.02.10
Notice concerning non-operating expenses
2022.02.10
Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
2022.01.31
Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
2022.01.18
SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
2022.01.06
Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo
2021.12.24
Notice of Appointment of Executive Vice President, Corporate Officer and COO
2021.12.20
Notice of Appointment of Corporate Officer
2021.12.06
Analyst Report[Follow-up Report] (Fair Research)
2021.12.03
Analyst Report[Full report] (Shared Research)
2021.11.24
SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
2021.11.11
Analyst Report[Update report] (Shared Research)
2021.11.11
Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.11.11
Notice Concerning Non-operating Expenses
2021.11.11
SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021 Financial Overview for the Third Quarter of the Fiscal Year
2021.11.11
SymBio announces selection of "Growth Market" as new market segment
2021.11.11
Message from President of SymBio Pharma USA
2021.10.12
SymBio announces commencement of operations of SymBio Pharma USA, Inc.
2021.09.29
SymBio announces presentation of the final results of its Phase 3 Clinical Trial of TREAKISYM in r/r DLBCL at the 83rd Annual Meeting of the Japanese Society of Hematology
2021.09.27
Onconova Therapeutics announces preliminary data on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
2021.09.21
Initiation of controls on shipments of TREAKISYM lyophilized injection formulation
2021.09.09
Analyst Report[Research Coverage Report] (Shared Research)
2021.09.08
SymBio announces initiation of non-clinical study of brincidofovir IV at the Brain Tumor Center, Department of Neurological Surgery University of California, San Francisco
2021.09.01
SymBio enters into a collaborative research agreement with the National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
2021.08.17
SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of anti-viral drug Brincidofovir IV
2021.08.04
Analyst Report[Update report] (Shared Research)
2021.08.04
Notice Concerning Non-operating Expenses
2021.08.04
Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.08.02
Collaborative research with Kyoto University on mechanism of response of bendamustine for diffuse large B-cell lymphoma
2021.07.15
Notice of Appointment of Corporate Officer
2021.07.15
Collaborative research with Gunma University to explore new indications for bendamustine and rigosertib
2021.06.29
Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer